Articles Vol. 65 No. CĐ10 - Bệnh viện Thống Nhất 30/10/2024

8. THE EFFICIENCY OF CHEMOTHERPY PLUS PEMBROLIZUMAB REGIMEN IN PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER, REAL-WORLD DATA OF THONG NHAT HOSPITAL

Tran Manh Hoang1,2, Do Kim Que1,2, Nguyen Thi Hong1,2, Pham Huu Tuyen1,2
1 Thong Nhat Hospital
2 Bệnh viện Thống Nhất
Corresponding author: manhhoang.tran@gmail.com
DOI: 10.52163/yhc.v65iCD10.1591
27 Views
16 Downloads
Keywords
chemotherapy combination Pembrolizumab regimen effective and safety stage IV NSCLC
Abstract

Background: The primary treatment of non-mutant, unresectable advanced non-small cell lung cancer(NSCLC) is mainly based on dual Platinum-based chemotherapy, adding immune checkpoint inhibitor to chemotherapy resulting in a higher response rate and survival compared with chemotherapy alone.

Objectives: Evaluation of efficacy and safety of chemotherapy in combination with Pembrolizumab regimen in patients with stage IV NSCLC without diver mutations.

Study subjects: All patients with stage IV NSCLC treated with Pembrolizumab at the Oncology Department of Thong Nhat Hospital from 1/2019 met the selection criteria. Methods: Retrospective descriptive case series in 1/2019 and cut-off data on 1/6/2023. Results: we enrolled 33 patients treated with chemotherapy combination pembrolizumab regimen. In this study, the response rate was 45.5%, the complete response was 8%; median time to treatment failure (TTF) 9 months; median overall survival 21 months; one case of grade 3 interstitial pneumonia, two cases of hepatitis, one case of diabetes, anemia and thrombocytopenia well controlled.

Conclusion: Treatment of stage IV NSCLC with chemotherapy combination Pembrolizumab regimen is effective and safe.

References
[1]
Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Nov 1 2002;20(21):4285-91. doi:10.1200/jco.2002.02.068 Google Scholar
[2]
Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung cancer (Amsterdam, Netherlands). Nov 2002;38 Suppl 2:S45-50. doi:10.1016/s0169-5002(02)00357-4 Google Scholar
[3]
Hiderito H, Nogami N, Saka H, et al. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Cancer science. Aug 2021;112(8):3255-3265. doi:10.1111/cas.14980 Google Scholar
[4]
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous NonSmall-Cell Lung Cancer. The New England journal of medicine. Nov 22 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865 Google Scholar
[5]
Gadgeel M. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–SmallCell Lung Cancer. in ASCO 2019. 2019;abtract#9013 Google Scholar
[6]
Sơn NT. Đánh giá hiệu quả và an toàn của các phác đồ có pembrlizumab trong điều trị bước một ung thư phổi không tế bào nhỏ gia đoạn di căn. Luận văn chuyên khoa 2. ĐH Y dược TPHCM; 2023. Google Scholar
[7]
Cheng Y, Zhang L, Hu J, et al. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407. JTO clinical and research reports. Oct 2021;2(10):100225. doi:10.1016/j.jtocrr.2021.100225 Google Scholar
[8]
Kobayashi M. Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC. 2021 Google Scholar